Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Surgical removal of the primary?—The role it plays in stage IV breast cancer

Surgical removal of the primary?—The role it plays in stage IV breast cancer Local therapy in synchronously metastasized disease is an uncommon strategy and usually not the first way to go. However, retrospective but also some prospective data suggest some kind of benefit with this treatment. Underlying mechanisms are not understood. This invited short review deals with the resection of the primary breast cancer in stage IV breast cancer patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Surgical removal of the primary?—The role it plays in stage IV breast cancer

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/surgical-removal-of-the-primary-the-role-it-plays-in-stage-iv-breast-6W0tEuDsl3
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0024-1
Publisher site
See Article on Publisher Site

Abstract

Local therapy in synchronously metastasized disease is an uncommon strategy and usually not the first way to go. However, retrospective but also some prospective data suggest some kind of benefit with this treatment. Underlying mechanisms are not understood. This invited short review deals with the resection of the primary breast cancer in stage IV breast cancer patients.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 15, 2012

References

  • Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor
    Babiera, GV; Rao, R; Feng, L
  • Association of surgery with improved survival in stage IV breast cancer patients
    Blanchard, DK; Shetty, PB; Hilsenbeck, SG
  • Does local surgery have a role in the management of stage IV breast cancer?
    Carmichael, AR; Anderson, ED; Chetty, U
  • Does aggressive local therapy improve survival in metastatic breast cancer?
    Khan, SA; Stewart, AK; Morrow, M
  • Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis
    Rapiti, E; Verkooijen, HM; Vlastos, G
  • Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data
    Gnerlich, J; Jeffe, DB; Deshpande, AD
  • Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Fisher, B; Anderson, S; Bryant, J
  • Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer
    Veronesi, U; Cascinelli, N; Mariani, L
  • Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
    Clarke, M; Collins, R; Darby, S
  • Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    Flanigan, RC; Salmon, SE; Blumenstein, BA
  • Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
    Mickisch, GH; Garin, A; van Poppel, H
  • Surgery of the primary tumor does not improve survival in stage IV breast cancer
    Dominici, L; Najita, J; Hughes, M
  • Is cancer a disease of self-seeding?
    Norton, L; Massague, J
  • Self-renewal and solid tumor stem cells
    Al-Hajj, M; Clarke, MF
  • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Bao, S; Wu, Q; McLendon, RE
  • Prospective identification of tumorigenic breast cancer cells
    Al-Hajj, M; Wicha, MS; Benito-Hernandez, A
  • Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor
    Kong, FM; Anscher, MS; Murase, T
  • TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
    Tang, B; Vu, M; Booker, T
  • Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects
    Yang, YA; Dukhanina, O; Tang, B
  • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
    Kim, KJ; Li, B; Winer, J
  • Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
    Linderholm, B; Grankvist, K; Wilking, N
  • Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers
    Linderholm, BK; Lindh, B; Beckman, L
  • Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer
    Nishimura, R; Nagao, K; Miyayama, H
  • Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment
    Wu, Y; Saldana, L; Chillar, R
  • Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes
    Kummel, S; Eggemann, H; Luftner, D
  • Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression
    Sharma, MR; Koltowski, L; Ownbey, RT
  • Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer
    Caine, GJ; Stonelake, PS; Lip, GY
  • Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery
    Curigliano, G; Petit, JY; Bertolini, F
  • A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation
    Joffe, JK; Banks, RE; Forbes, MA
  • Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
    Wagner, JR; Walther, MM; Linehan, WM
  • Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer
    Boughey, JC; Hoskin, TL; Degnim, AC